Publications

Frankenfeld CL. 2022. Fecal metabolome: New addition to the toolbox for dietary assessment? J Nutr 152(12):2643–2644; doi: 10.1093/jn/nxac233. PMID: 36288243.

Jensen I, Cyr P. 2022. Early health economic models in gene and cell therapy to inform clinical trial design and optimize commercialization efforts. White Paper. PharmaLive.

Yao W, Jensen I, Claussen M, Dandurand K, Buffington B, Fuentes D, Mikhael M. 2022. Health economics of selective early rescue surfactant administration and standard surfactant administration for newborns with respiratory distress syndrome. J Pediatr Pharmacol Ther 27(8):695–702; doi:  10.5863/1551-6776-27.8.695.

Sacks NC. Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US. Poster presentation, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe, November 2022.

Woo K, Fuld R, Grandinetti A, Lawson J, Litchfield T, Ohan M, Peipert JD, Rivara MB, Nordyke RJ. 2022. Patient-reported outcomes in hemodialysis vascular access: A call to action. J Vasc Access 23(6):973-980; doi: 10.1177/11297298211018295. PMID: 34032166.

Cohen SS, Bylsma LC, Movva N, Alexander DD. 2022. Theoretical attributable risk analysis and Disability Adjusted Life Years (DALYs) based on increased dairy consumption. BMC Public Health 22(1):1625; doi: 10.1186/s12889-022-14042-7. PMID: 36030208.

Frankenfeld CL. Biostatistical approaches in gut microbiome research. Presentation for American Society of Nutrition-Institute for the Advancement of Food and Nutrition Science Collaborative Session “Sample Collection, Preservation, and Data Analysis in Gut Microbiome Research: Current Methods and Potential Impact on Results,” October 13, 2022.

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer.  Adv Ther 39(6):2778–2795; doi:10.1007/s12325-022-02141-1. PMID: 35430673.

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338; doi: 10.1007/s00520-022-06967-x. PMID: 35482126.